CME Group Cl A had its Relative Strength (RS) Rating upgraded from 69 to 72 Friday — a welcome improvement, but still short of the 80 or better score you look for.
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 as they begin their biggest price moves. See if CME Group Cl A can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
The stock, which is on the IBD Big Cap 20 list, is trying to complete a flat base with a 249.02 entry. See if it can break out in volume at least 40% above average.
In terms of fundamentals, CME Group Cl A has posted rising EPS growth over the last two quarters. Revenue gains have also moved higher over the same time frame. The company is expected to report its next quarterly numbers on or around Feb. 12.
CME Group Cl A earns the No. 4 rank among its peers in the Financial Services-Specialty industry group. Marex Group is the top-ranked stock within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
